肥胖与肾小球疾病患者肾脏及心脏结局的关联:CureGN网络研究
该研究基于CureGN前瞻性多中心观察性研究,纳入2301例肾小球疾病患者(1548例成人,753例儿童),分析肥胖与复合肾脏结局(eGFR下降40%或肾衰竭)及复合心血管结局的关联。成人2-3级肥胖在未调整分析中与肾脏结局相关(HR 1.6,95%CI 1.1-2.2,P=0.006),但调整基线eGFR和蛋白尿后不再显著;2-3级肥胖与心血管结局风险升高独立相关(HR 3.9,95%CI 1.4-10.7,P=0.009)。
要点
- 成人2-3级肥胖与心血管复合结局风险升高独立相关。
- 调整基线eGFR和蛋白尿后,肥胖与肾脏复合结局的关联不再显著。
- 儿童肥胖与肾脏或心血管结局的关联未报告显著结果。
核心结论
- 在CureGN成人患者中,2-3级肥胖与心血管结局相关,但调整潜在混杂因素后与肾脏结局无关。
研究设计与样本
- 前瞻性、多中心、观察性研究,纳入CureGN网络中年龄≥5岁的2301例参与者(1548例成人,753例儿童)。
主要发现
- 成人2-3级肥胖者主要肾脏终点发生率为90.8/1000人年,正常体重者为58.0/1000人年。
- 未调整分析中,成人2-3级肥胖与肾脏复合结局相关(HR 1.6,95%CI 1.1-2.2,P=0.006)。
- 多变量调整基线eGFR和蛋白尿后,成人2-3级肥胖与肾脏结局的关联不再显著。
- 成人2-3级肥胖者心血管事件发生率为19.7/1000人年,完全调整模型中心血管风险升高(HR 3.9,95%CI 1.4-10.7,P=0.009)。
关键数值与推荐
- 成人BMI分组:20-24为健康体重,25-34为超重/1级肥胖,≥35为2-3级肥胖。
- 儿童BMI百分位分组:5-84为健康体重,85-94为超重,≥95为肥胖。
- 复合肾脏结局定义为eGFR下降40%或肾衰竭。
- 复合心血管结局定义为心肌梗死、卒中、心力衰竭或死亡。
临床怎么用
- 对肾小球疾病成人患者,应关注2-3级肥胖者的心血管风险评估与管理。
- 肥胖对肾脏结局的影响可能受基线肾功能和蛋白尿水平影响,需个体化评估。
局限性
- BMI是肥胖的不完美指标。
- 可能存在社会经济因素的残余混杂。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
RATIONALE & OBJECTIVE: The influence of obesity on cardiorenal outcomes in individuals with glomerular disease is incompletely known. This study examined the association between obesity and kidney and cardiovascular outcomes in children and adults with glomerular kidney disease. STUDY DESIGN: Prospective, multicenter, observational study. SETTING & PARTICIPANTS: Participants in the Cure Glomerulonephropathy Network (CureGN) who were≥5 years of age at enrollment. EXPOSURE: Adult body mass index (BMI) groups: 20-24 (healthy) versus 25-34 (overweight/class 1 obesity) versus≥35 (class 2-3 obesity); and pediatric BMI percentiles: 5th-84th (healthy) versus 85th-94th (overweight) versus≥95th (obese). OUTCOME: A composite kidney outcome (40% estimated glomerular filtration rate [eGFR] decline or kidney failure) and a composite cardiovascular outcome (myocardial infarction, stroke, heart failure, or death). ANALYTICAL APPROACH: Time to composite primary outcomes by BMI strata were estimated using Kaplan-Meier analysis. The adjusted associations between BMI and outcomes were estimated using Cox proportional hazards analysis. RESULTS: The study included 2,301 participants (1,548 adults and 753 children). The incidence of the primary kidney end point was 90.8 per 1,000 person-years in adults with class 2-3 obesity, compared with 58.0 in normal weight comparators. In the univariable analysis, class 2-3 obesity was associated with the primary kidney outcome only in adults (HR, 1.6 [95% CI, 1.1-2.2], P=0.006) compared with the healthy weight groups. In the multivariable adjusted analysis, class 2-3 obesity did not remain significant among adults when controlling for baseline eGFR and proteinuria. Adults with class 2-3 obesity had an incidence of 19.7 cardiovascular events per 1,000 person-years and greater cardiovascular risk (HR, 3.9 [95% CI, 1.4-10.7], P=0.009) in the fully adjusted model. LIMITATIONS: BMI is an imperfect indicator of adiposity. Residual confounding may exist from socioeconomic factors. CONCLUSIONS: Among adult patients in CureGN, class 2-3 obesity is associated with cardiovascular but not kidney outcomes when adjusted for potential confounding factors. PLAIN-LANGUAGE SUMMARY: Obesity is a risk factor for adverse heart and kidney outcomes in patients with chronic kidney disease, but whether it is associated with these outcomes in patients with glomerulonephropathy is not known. This study used existing data from a large sample of adults and children with glomerular diseases to address this question. The findings suggest that obesity increases the risk of cardiovascular but not kidney disease events in adult patients with glomerular disease.
引用
- Zeitler EM, Glenn DA, Hu Y, et al. Association of Obesity With Kidney and Cardiac Outcomes Among Patients With Glomerular Disease: Findings From the Cure Glomerulonephropathy Network. Am J Kidney Dis. 2024. PMID: 38750877. doi:10.1053/j.ajkd.2024.03.020
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。